Trevi Therapeutics, Inc. Operating Expenses
Trevi Therapeutics, Inc. (TRVI) reported Operating Expenses of $20.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Trevi Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $20.51M, a 49.46% increase year-over-year.
- Trevi Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $14.91M, a 30.01% increase year-over-year.
- Trevi Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $10.22M, a 16.52% decline year-over-year.
- Trevi Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $13.92M, a 1.21% decline year-over-year.
- Trevi Therapeutics, Inc. operating expenses for fiscal 2025 was $49.33M, a 4.26% decline from fiscal 2024.
- Trevi Therapeutics, Inc. operating expenses for fiscal 2024 was $51.52M, a 51.89% increase from fiscal 2023.
- Trevi Therapeutics, Inc. operating expenses for fiscal 2023 was $33.92M, a 13.43% increase from fiscal 2022.
- Trevi Therapeutics, Inc. operating expenses for fiscal 2022 was $29.91M, a 7.91% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.51M 10-Q · filed 2026-08-06 | $35.42M 10-Q · filed 2026-08-06 | $45.64M derived: sum of 3 quarters · filed 2026-08-06 | $59.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.91M 10-Q · filed 2026-05-05 | $25.13M derived: sum of 2 quarters · filed 2026-05-05 | $39.05M derived: sum of 3 quarters · filed 2026-05-05 | $52.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $24.14M derived: sum of 2 quarters · filed 2026-03-17 | $37.86M derived: sum of 3 quarters · filed 2026-08-06 | $49.33M 10-K · filed 2026-03-17 |
| 2025-09-30 | $13.92M 10-Q · filed 2025-11-13 | $27.64M derived: sum of 2 quarters · filed 2026-08-06 | $39.11M 10-Q · filed 2025-11-13 | $51.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.72M 10-Q · filed 2026-08-06 | $25.19M 10-Q · filed 2026-08-06 | $37.44M derived: sum of 3 quarters · filed 2026-08-06 | $51.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.47M 10-Q · filed 2026-05-05 | $23.71M derived: sum of 2 quarters · filed 2026-05-05 | $37.80M derived: sum of 3 quarters · filed 2026-05-05 | $51.09M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $26.33M derived: sum of 2 quarters · filed 2026-03-17 | $39.62M derived: sum of 3 quarters · filed 2026-03-17 | $51.52M 10-K · filed 2026-03-17 |
| 2024-09-30 | $14.09M 10-Q · filed 2025-11-13 | $27.38M derived: sum of 2 quarters · filed 2025-11-13 | $39.28M 10-Q · filed 2025-11-13 | $48.22M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $13.29M 10-Q · filed 2025-08-07 | $25.20M 10-Q · filed 2025-08-07 | $34.13M derived: sum of 3 quarters · filed 2025-08-07 | $43.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $11.91M 10-Q · filed 2025-05-08 | $20.84M derived: sum of 2 quarters · filed 2025-05-08 | $29.88M derived: sum of 3 quarters · filed 2025-05-08 | $38.27M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $8.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $17.98M derived: sum of 2 quarters · filed 2025-03-18 | $26.36M derived: sum of 3 quarters · filed 2025-03-18 | $33.92M 10-K · filed 2025-03-18 |
| 2023-09-30 | $9.04M 10-Q · filed 2024-11-06 | $17.43M derived: sum of 2 quarters · filed 2024-11-06 | $24.99M 10-Q · filed 2024-11-06 | $31.65M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $8.38M 10-Q · filed 2024-08-08 | $15.95M 10-Q · filed 2024-08-08 | $22.60M derived: sum of 3 quarters · filed 2024-08-08 | $31.01M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $7.56M 10-Q · filed 2024-05-07 | $14.22M derived: sum of 2 quarters · filed 2024-05-07 | $22.63M derived: sum of 3 quarters · filed 2024-05-07 | $30.45M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $15.06M derived: sum of 2 quarters · filed 2024-03-20 | $22.88M derived: sum of 3 quarters · filed 2024-03-20 | $29.91M 10-K · filed 2024-03-20 |
| 2022-09-30 | $8.40M 10-Q · filed 2023-11-09 | $16.23M derived: sum of 2 quarters · filed 2023-11-09 | $23.25M 10-Q · filed 2023-11-09 | $31.52M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $7.82M 10-Q · filed 2023-08-10 | $14.85M 10-Q · filed 2023-08-10 | $23.12M derived: sum of 3 quarters · filed 2023-08-10 | $30.07M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $7.03M 10-Q · filed 2023-05-11 | $15.30M derived: sum of 2 quarters · filed 2023-05-11 | $22.25M derived: sum of 3 quarters · filed 2023-05-11 | $31.41M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $15.22M derived: sum of 2 quarters · filed 2023-03-16 | $24.39M derived: sum of 3 quarters · filed 2023-03-16 | $32.48M 10-K · filed 2023-03-16 |
| 2021-09-30 | $6.95M 10-Q · filed 2022-11-10 | $16.11M derived: sum of 2 quarters · filed 2022-11-10 | $24.20M 10-Q · filed 2022-11-10 | $33.40M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $9.17M 10-Q · filed 2022-08-11 | $17.26M 10-Q · filed 2022-08-11 | $26.45M derived: sum of 3 quarters · filed 2022-08-11 | $33.69M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $8.09M 10-Q · filed 2022-05-12 | $17.28M derived: sum of 2 quarters · filed 2022-05-12 | $24.53M derived: sum of 3 quarters · filed 2022-05-12 | $31.94M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $16.44M derived: sum of 2 quarters · filed 2022-03-17 | $23.85M derived: sum of 3 quarters · filed 2022-03-17 | $32.49M 10-K · filed 2022-03-17 |
| 2020-09-30 | $7.24M 10-Q · filed 2021-11-10 | $14.66M derived: sum of 2 quarters · filed 2021-11-10 | $23.30M 10-Q · filed 2021-11-10 | $30.06M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $7.41M 10-Q · filed 2021-08-12 | $16.05M 10-Q · filed 2021-08-12 | $22.82M derived: sum of 3 quarters · filed 2021-08-12 | $30.47M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $8.64M 10-Q · filed 2021-05-13 | $15.40M derived: sum of 2 quarters · filed 2021-05-13 | $23.05M derived: sum of 3 quarters · filed 2021-05-13 | $30.47M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $14.42M derived: sum of 2 quarters · filed 2021-03-25 | $21.83M derived: sum of 3 quarters · filed 2021-03-25 | $26.64M 10-K · filed 2021-03-25 |
| 2019-09-30 | $7.65M 10-Q · filed 2020-11-12 | $15.07M derived: sum of 2 quarters · filed 2020-11-12 | $19.88M 10-Q · filed 2020-11-12 | $25.81M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $7.42M 10-Q · filed 2020-08-13 | $12.23M 10-Q · filed 2020-08-13 | $18.16M derived: sum of 3 quarters · filed 2020-08-13 | $23.11M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $4.81M 10-Q · filed 2020-05-07 | $10.74M derived: sum of 2 quarters · filed 2020-05-07 | $15.70M derived: sum of 3 quarters · filed 2020-05-07 | $20.08M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $5.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $10.89M derived: sum of 2 quarters · filed 2020-03-16 | $15.27M derived: sum of 3 quarters · filed 2020-03-16 | $18.41M 10-K · filed 2020-03-16 |
| 2018-09-30 | $4.96M 10-Q · filed 2019-11-14 | $9.34M derived: sum of 2 quarters · filed 2019-11-14 | $12.48M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $4.38M 10-Q · filed 2019-08-12 | $7.52M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $3.14M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |